M Beth McCarville1, Jamie L Coleman1, Junyu Guo1, Yimei Li2, Xingyu Li2, Patricia J Honnoll1, Andrew M Davidoff3, Fariba Navid4,5. 1. 1 Department of Diagnostic Imaging (MS 220), St. Jude Children's Research Hospital, 262 Danny Thomas Pl, Memphis, TN 38105. 2. 2 Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, TN. 3. 3 Department of Surgery, St. Jude Children's Research Hospital, Memphis, TN. 4. 4 Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN. 5. 5 Present address: McLean, VA.
Abstract
OBJECTIVE: The purpose of this study was to investigate contrast-enhanced ultrasound assessment of tumor response to antiangiogenic therapy in children and adolescents with solid malignancies. SUBJECTS AND METHODS: Children with recurrent solid tumors who were enrolled in an institutional phase 1 study of antiangiogenic therapy underwent contrast-enhanced ultrasound of target lesions before therapy, on therapy days 3 and 7, and at the end of course 1. Acoustic data from target lesion ROIs were used to measure peak enhancement, time to peak, rate of enhancement, total AUC, AUC during wash-in (AUC1), and AUC during washout (AUC2). The Cox regression model was used to assess the association between changes in parameters from baseline to follow-up time points and time to tumor progression. Values of p ≤ 0.050 were considered significant. RESULTS: Target lesion sites included liver (n = 3), pleura (n = 2), and supraclavicular mass, soft-tissue component of bone metastasis, lung, retroperitoneum, peritoneum, lymph node, muscle mass, and perineum (n = 1 each). Hazard ratios for changes from baseline to end of course 1 for peak enhancement (1.17, p = 0.034), rate of enhancement (3.25, p = 0.029), and AUC1 (1.02, p = 0.040) were significantly associated with time to progression. Greater decreases in these parameters correlated with longer time to progression. CONCLUSION: Contrast-enhanced ultrasound measurements of tumor peak enhancement, rate of enhancement, and AUC1 were early predictors of time to progression in a cohort of children and adolescents with recurrent solid tumors treated with antiangiogenic therapy. Further investigation of these findings in a larger population is warranted.
OBJECTIVE: The purpose of this study was to investigate contrast-enhanced ultrasound assessment of tumor response to antiangiogenic therapy in children and adolescents with solid malignancies. SUBJECTS AND METHODS: Children with recurrent solid tumors who were enrolled in an institutional phase 1 study of antiangiogenic therapy underwent contrast-enhanced ultrasound of target lesions before therapy, on therapy days 3 and 7, and at the end of course 1. Acoustic data from target lesion ROIs were used to measure peak enhancement, time to peak, rate of enhancement, total AUC, AUC during wash-in (AUC1), and AUC during washout (AUC2). The Cox regression model was used to assess the association between changes in parameters from baseline to follow-up time points and time to tumor progression. Values of p ≤ 0.050 were considered significant. RESULTS: Target lesion sites included liver (n = 3), pleura (n = 2), and supraclavicular mass, soft-tissue component of bone metastasis, lung, retroperitoneum, peritoneum, lymph node, muscle mass, and perineum (n = 1 each). Hazard ratios for changes from baseline to end of course 1 for peak enhancement (1.17, p = 0.034), rate of enhancement (3.25, p = 0.029), and AUC1 (1.02, p = 0.040) were significantly associated with time to progression. Greater decreases in these parameters correlated with longer time to progression. CONCLUSION: Contrast-enhanced ultrasound measurements of tumor peak enhancement, rate of enhancement, and AUC1 were early predictors of time to progression in a cohort of children and adolescents with recurrent solid tumors treated with antiangiogenic therapy. Further investigation of these findings in a larger population is warranted.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: Fariba Navid; Sharyn D Baker; M Beth McCarville; Clinton F Stewart; Catherine A Billups; Jianrong Wu; Andrew M Davidoff; Sheri L Spunt; Wayne L Furman; Lisa M McGregor; Shuiying Hu; John C Panetta; David Turner; Demba Fofana; Wilburn E Reddick; Wing Leung; Victor M Santana Journal: Clin Cancer Res Date: 2012-11-08 Impact factor: 12.531
Authors: Paxton V Dickson; John B Hamner; Christian J Streck; Catherine Y C Ng; M Beth McCarville; Christopher Calabrese; Richard J Gilbertson; Clinton F Stewart; Christy M Wilson; M Waleed Gaber; Lawrence M Pfeffer; Stephen X Skapek; Amit C Nathwani; Andrew M Davidoff Journal: Mol Cancer Res Date: 2007-06 Impact factor: 5.852
Authors: Paxton V Dickson; John B Hamner; Thomas L Sims; Charles H Fraga; Catherine Y C Ng; Surender Rajasekeran; Nikolaus L Hagedorn; M Beth McCarville; Clinton F Stewart; Andrew M Davidoff Journal: Clin Cancer Res Date: 2007-07-01 Impact factor: 12.531
Authors: Vasileios Rafailidis; Annamaria Deganello; Tom Watson; Paul S Sidhu; Maria E Sellars Journal: Br J Radiol Date: 2016-09-26 Impact factor: 3.039
Authors: Matthew A Thimm; Daniel Rhee; Clifford M Takemoto; Wikrom Karnsakul; Carmen Cuffari; Anthony L Guerrerio; Alejandro Garcia; John Gearhart; Thierry A G M Huisman; Misun Hwang Journal: Eur J Pediatr Date: 2018-07-03 Impact factor: 3.183
Authors: Cheng Fang; Sudha A Anupindi; Susan J Back; Doris Franke; Thomas G Green; Zoltan Harkanyi; Jörg Jüngert; Jeannie K Kwon; Harriet J Paltiel; Judy H Squires; Vassil N Zefov; M Beth McCarville Journal: Pediatr Radiol Date: 2021-05-12
Authors: Vasileios Rafailidis; Savvas Andronikou; Hans-Joachim Mentzel; Maciej Piskunowicz; Judy H Squires; Carol E Barnewolt Journal: Pediatr Radiol Date: 2021-05-12